19 results on '"Raz N"'
Search Results
2. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E., Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, and Friberg, Lena E.
- Abstract
OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.
- Published
- 2020
- Full Text
- View/download PDF
3. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E., Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, and Friberg, Lena E.
- Abstract
OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.
- Published
- 2020
- Full Text
- View/download PDF
4. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, A.N. (A. N.), Rognås, V. (V.), Brill, M.J.E. (Margreke J.E.), Dishon-Benattar, Y. (Y.), Durante-Mangoni, E. (Emanuele), Daitch, V. (V.), Skiada, A. (A.), Lellouche, J. (J.), Nutman, A. (A.), Kotsaki, A. (A.), Andini, R. (R.), Eliakim-Raz, N. (Noa), Bitterman, R. (R.), Antoniadou, A. (A.), Karlsson, M.O. (M. O.), Theuretzbacher, U. (Ursula), Leibovici, L. (Leonard), Daikos, G.L. (George), Mouton, J.W. (Johan), Carmeli, Y. (Yehuda), Paul, M. (Mical), Friberg, L.E. (Lena), Kristoffersson, A.N. (A. N.), Rognås, V. (V.), Brill, M.J.E. (Margreke J.E.), Dishon-Benattar, Y. (Y.), Durante-Mangoni, E. (Emanuele), Daitch, V. (V.), Skiada, A. (A.), Lellouche, J. (J.), Nutman, A. (A.), Kotsaki, A. (A.), Andini, R. (R.), Eliakim-Raz, N. (Noa), Bitterman, R. (R.), Antoniadou, A. (A.), Karlsson, M.O. (M. O.), Theuretzbacher, U. (Ursula), Leibovici, L. (Leonard), Daikos, G.L. (George), Mouton, J.W. (Johan), Carmeli, Y. (Yehuda), Paul, M. (Mical), and Friberg, L.E. (Lena)
- Abstract
Objectives: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. Methods: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. Results: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14–1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03–1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19–1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. Discussion: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >
- Published
- 2020
- Full Text
- View/download PDF
5. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E., Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, and Friberg, Lena E.
- Abstract
OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.
- Published
- 2020
- Full Text
- View/download PDF
6. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E., Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, and Friberg, Lena E.
- Abstract
OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.
- Published
- 2020
- Full Text
- View/download PDF
7. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E., Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, and Friberg, Lena E.
- Abstract
OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.
- Published
- 2020
- Full Text
- View/download PDF
8. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, AN, Rognas, V, Brill, MJE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, MO, Theuretzbacher, U, Leibovici, L, Daikos, GL, Mouton, Johan, Carmeli, Y, Paul, M, Friberg, LE, Kristoffersson, AN, Rognas, V, Brill, MJE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, MO, Theuretzbacher, U, Leibovici, L, Daikos, GL, Mouton, Johan, Carmeli, Y, Paul, M, and Friberg, LE
- Published
- 2020
9. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Author
-
Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E., Kristoffersson, Anders N., Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, and Friberg, Lena E.
- Abstract
OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death. METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis. RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen. DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.
- Published
- 2020
- Full Text
- View/download PDF
10. Neuigkeiten aus der Achromatopsie. Mehr als nur Schwarz-Weiß?
- Author
-
Herbik, A, Molz, B, Baseler, H, Raz, N, Best, Pd, Ahmadi, K, Gottlob, I, Choritz, L, Gouws, A, Lowndes, R, Maguire, J, Kanowski, M, Käsmann-Kellner, B, Wieland, I, Banin, E, Levin, N, Morland, AB, Hoffmann, MB, Herbik, A, Molz, B, Baseler, H, Raz, N, Best, Pd, Ahmadi, K, Gottlob, I, Choritz, L, Gouws, A, Lowndes, R, Maguire, J, Kanowski, M, Käsmann-Kellner, B, Wieland, I, Banin, E, Levin, N, Morland, AB, and Hoffmann, MB
- Published
- 2019
11. Neuigkeiten aus der Achromatopsie. Mehr als nur Schwarz-Weiß?
- Author
-
Herbik, A, Molz, B, Baseler, H, Raz, N, Best, Pd, Ahmadi, K, Gottlob, I, Choritz, L, Gouws, A, Lowndes, R, Maguire, J, Kanowski, M, Käsmann-Kellner, B, Wieland, I, Banin, E, Levin, N, Morland, AB, Hoffmann, MB, Herbik, A, Molz, B, Baseler, H, Raz, N, Best, Pd, Ahmadi, K, Gottlob, I, Choritz, L, Gouws, A, Lowndes, R, Maguire, J, Kanowski, M, Käsmann-Kellner, B, Wieland, I, Banin, E, Levin, N, Morland, AB, and Hoffmann, MB
- Published
- 2019
12. Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: The COMBACTE-MAGNET RESCUING study
- Author
-
Universitat Rovira i Virgili, Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Tebé C, Wolkewitz M, Wiegand I, Grier S, Vank C, Cuperus N, Van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, Pujol M, RESCUING Study Group and Study Sites, Universitat Rovira i Virgili, and Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Tebé C, Wolkewitz M, Wiegand I, Grier S, Vank C, Cuperus N, Van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, Pujol M, RESCUING Study Group and Study Sites
- Abstract
© 2019 The Author(s). Background: Although catheter-associated urinary tract infection (CA-UTI) is a major healthcare-related problem worldwide, there is a scarcity of current data from countries with high antimicrobial resistance rates. We aimed to determine the clinical outcomes of patients with CA-UTI compared to those of patients with other sources of complicated urinary tract infection (cUTI), and to assess the impact of antimicrobial resistance. We also aimed to identify the factors influencing 30-day mortality among patients with CA-UTI. Methods: This was a multicentre, multinational retrospective cohort study including hospitalised adults with cUTI between January 2013 and December 2014 in twenty hospitals from eight countries from southern Europe, Turkey and Israel. The primary endpoint was 30-day mortality. The secondary endpoints were length of hospital stay, symptom improvement after 7 days' treatment, symptom recurrence at 30 days and readmission 60 days after hospital discharge. Results: Of the 807 cUTI episodes, 341 (42.2%) were CA-UTIs. The time from catheter insertion to cUTI diagnosis was less than 2 weeks in 44.6% of cases. Overall, 74.5% of cases had hospital or healthcare-acquired CA-UTI. Compared to patients with other cUTI aetiologies, those with CA-UTI had the following characteristics: They were more frequently males, older, admitted for a reason other than cUTI and admitted from a long-term care facility; had higher Charlson's comorbidity index; and more frequently had polymicrobial infections and multidrug-resistant Gram-negative bacteria (MDR-GNB). Patients with CA-UTI also had significantly higher 30-day mortality rates (15.2% vs 6%) and longer hospital stay (median 14 [interquartile range-IQR-7-27] days vs 8 [IQR 5-14] days) than patients w
- Published
- 2019
13. High-sensitivity refractive index sensor based on large-angle tilted fiber grating with carbon nanotube deposition
- Author
-
Berghmans, Francis, Mignani, Anna G., Badmos, Abdulyezir A., Sun, Qizhen, Yan, Zhijun, Arif, Raz N., Zhang, Junxi, Rozhin, Alex, Zhang, Lin, Berghmans, Francis, Mignani, Anna G., Badmos, Abdulyezir A., Sun, Qizhen, Yan, Zhijun, Arif, Raz N., Zhang, Junxi, Rozhin, Alex, and Zhang, Lin
- Abstract
This paper presents a highly sensitive ambient refractive index (RI) sensor based on 81° tilted fiber grating (81°-TFG) structure UV-inscribed in standard telecom fiber (62.5μm cladding radius) with carbon nanotube (CNT) overlay deposition. The sensing mechanism is based on the ability of CNT to induce change in transmitted optical power and the high sensitivity of 81°-TFG to ambient refractive index. The thin CNT film with high refractive index enhances the cladding modes of the TFG, resulting in the significant interaction between the propagating light and the surrounding medium. Consequently, the surrounding RI change will induce not only the resonant wavelength shift but also the power intensity change of the attenuation band in the transmission spectrum. Result shows that the change in transmitted optical power produces a corresponding linear reduction in intensity with increment in RI values. The sample shows high sensitivities of ∼207.38nm/RIU, ∼241.79nm/RIU at RI range 1.344-1.374 and ∼113.09nm/RIU, ∼144.40nm/RIU at RI range 1.374-1.392 (for X-pol and Y-pol respectively). It also shows power intensity sensitivity of ∼ 65.728dBm/RIU and ∼ 45.898 (for X-pol and Y-pol respectively). The low thermal sensitivity property of the 81°-TFG offers reduction in thermal cross-sensitivity and enhances specificity of the sensor.
- Published
- 2016
14. High-sensitivity refractive index sensor based on large-angle tilted fiber grating with carbon nanotube deposition
- Author
-
Berghmans, Francis, Mignani, Anna G., Badmos, Abdulyezir A., Sun, Qizhen, Yan, Zhijun, Arif, Raz N., Zhang, Junxi, Rozhin, Alex, Zhang, Lin, Berghmans, Francis, Mignani, Anna G., Badmos, Abdulyezir A., Sun, Qizhen, Yan, Zhijun, Arif, Raz N., Zhang, Junxi, Rozhin, Alex, and Zhang, Lin
- Abstract
This paper presents a highly sensitive ambient refractive index (RI) sensor based on 81° tilted fiber grating (81°-TFG) structure UV-inscribed in standard telecom fiber (62.5μm cladding radius) with carbon nanotube (CNT) overlay deposition. The sensing mechanism is based on the ability of CNT to induce change in transmitted optical power and the high sensitivity of 81°-TFG to ambient refractive index. The thin CNT film with high refractive index enhances the cladding modes of the TFG, resulting in the significant interaction between the propagating light and the surrounding medium. Consequently, the surrounding RI change will induce not only the resonant wavelength shift but also the power intensity change of the attenuation band in the transmission spectrum. Result shows that the change in transmitted optical power produces a corresponding linear reduction in intensity with increment in RI values. The sample shows high sensitivities of ∼207.38nm/RIU, ∼241.79nm/RIU at RI range 1.344-1.374 and ∼113.09nm/RIU, ∼144.40nm/RIU at RI range 1.374-1.392 (for X-pol and Y-pol respectively). It also shows power intensity sensitivity of ∼ 65.728dBm/RIU and ∼ 45.898 (for X-pol and Y-pol respectively). The low thermal sensitivity property of the 81°-TFG offers reduction in thermal cross-sensitivity and enhances specificity of the sensor.
- Published
- 2016
15. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
- Author
-
Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., Antoniadou, A., Carmeli, Y., Nutman, A., Levi, I., Adler, A., Durante-Mangoni, E., Andini, R., Cavezza, G., Mouton †, J.W., Wijma, R.A., Theuretzbacher, U., Friberg, L.E., Kristoffersson, A.N., Zusman, O., Koppel, F., Benattar, Y.D., Altunin, S., Paul, M., et al., Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., Antoniadou, A., Carmeli, Y., Nutman, A., Levi, I., Adler, A., Durante-Mangoni, E., Andini, R., Cavezza, G., Mouton †, J.W., Wijma, R.A., Theuretzbacher, U., Friberg, L.E., Kristoffersson, A.N., Zusman, O., Koppel, F., Benattar, Y.D., Altunin, S., Paul, M., and et al.
- Abstract
Contains fulltext : 171002.pdf (publisher's version ) (Open Access)
- Published
- 2016
16. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant gram-negative infections (AIDA)
- Author
-
Dickstein, Y. (Yaakov), Leibovici, L. (Leonard), Yahav, D. (Dafna), Eliakim-Raz, N. (Noa), Daikos, G.L. (George), Skiada, A. (Anna), Antoniadou, A. (A.), Carmeli, Y. (Yehuda), Nutman, A. (Amir), Levi, I. (Inbar), Adler, A., Durante-Mangoni, E. (Emanuele), Andini, R. (Roberto), Cavezza, G. (Giusi), Mouton, J.W. (Johan), Wijma, R.A. (Rixt), Theuretzbacher, U. (Ursula), Friberg, L.E. (Lena), Kristoffersson, A.N. (Anders N), Zusman, O. (Oren), Koppel, F. (Fidi), Benattar, Y.D. (Yael Dishon), Altunin, S. (Sergey), Paul, M. (Mical), Dickstein, Y. (Yaakov), Leibovici, L. (Leonard), Yahav, D. (Dafna), Eliakim-Raz, N. (Noa), Daikos, G.L. (George), Skiada, A. (Anna), Antoniadou, A. (A.), Carmeli, Y. (Yehuda), Nutman, A. (Amir), Levi, I. (Inbar), Adler, A., Durante-Mangoni, E. (Emanuele), Andini, R. (Roberto), Cavezza, G. (Giusi), Mouton, J.W. (Johan), Wijma, R.A. (Rixt), Theuretzbacher, U. (Ursula), Friberg, L.E. (Lena), Kristoffersson, A.N. (Anders N), Zusman, O. (Oren), Koppel, F. (Fidi), Benattar, Y.D. (Yael Dishon), Altunin, S. (Sergey), and Paul, M. (Mical)
- Abstract
__Introduction:__ The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective and more toxic than modern antibiotics. In vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomised controlled study is necessary for clarification. __Methods and analysis:__ This is a multicentre, investigator-initiated, open-label, randomised controlled superiority 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy for infections caused by carbapenem-resistant Gramnegative bacteria. The study is being conducted in 6 centres in 3 countries (Italy, Greece and Israel). We include patients with hospital-associated and ventilatorassociated pneumonia, bloodstream infections and urosepsis. The prim
- Published
- 2016
- Full Text
- View/download PDF
17. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
- Author
-
Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., Antoniadou, A., Carmeli, Y., Nutman, A., Levi, I., Adler, A., Durante-Mangoni, E., Andini, R., Cavezza, G., Mouton †, J.W., Wijma, R.A., Theuretzbacher, U., Friberg, L.E., Kristoffersson, A.N., Zusman, O., Koppel, F., Benattar, Y.D., Altunin, S., Paul, M., et al., Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., Antoniadou, A., Carmeli, Y., Nutman, A., Levi, I., Adler, A., Durante-Mangoni, E., Andini, R., Cavezza, G., Mouton †, J.W., Wijma, R.A., Theuretzbacher, U., Friberg, L.E., Kristoffersson, A.N., Zusman, O., Koppel, F., Benattar, Y.D., Altunin, S., Paul, M., and et al.
- Abstract
Contains fulltext : 171002.pdf (publisher's version ) (Open Access)
- Published
- 2016
18. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
- Author
-
Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., Antoniadou, A., Carmeli, Y., Nutman, A., Levi, I., Adler, A., Durante-Mangoni, E., Andini, R., Cavezza, G., Mouton †, J.W., Wijma, R.A., Theuretzbacher, U., Friberg, L.E., Kristoffersson, A.N., Zusman, O., Koppel, F., Benattar, Y.D., Altunin, S., Paul, M., et al., Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., Antoniadou, A., Carmeli, Y., Nutman, A., Levi, I., Adler, A., Durante-Mangoni, E., Andini, R., Cavezza, G., Mouton †, J.W., Wijma, R.A., Theuretzbacher, U., Friberg, L.E., Kristoffersson, A.N., Zusman, O., Koppel, F., Benattar, Y.D., Altunin, S., Paul, M., and et al.
- Abstract
Contains fulltext : 171002.pdf (publisher's version ) (Open Access)
- Published
- 2016
19. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
- Author
-
Dickstein, Y, Leibovici, L, Yahav, D, Eliakim-Raz, N, Daikos, GL, Skiada, A, Antoniadou, A, Carmeli, Y, Nutman, A, Levi, I, Adler, A, Durante-Mangoni, E, Andini, R, Cavezza, G, Mouton, Johan, Wijma, Rixt, Theuretzbacher, U, Friberg, LE, Kristoffersson, AN, Zusman, O, Koppel, F, Benattar, YD, Altunin, S, Paul, M, Dickstein, Y, Leibovici, L, Yahav, D, Eliakim-Raz, N, Daikos, GL, Skiada, A, Antoniadou, A, Carmeli, Y, Nutman, A, Levi, I, Adler, A, Durante-Mangoni, E, Andini, R, Cavezza, G, Mouton, Johan, Wijma, Rixt, Theuretzbacher, U, Friberg, LE, Kristoffersson, AN, Zusman, O, Koppel, F, Benattar, YD, Altunin, S, and Paul, M
- Abstract
Introduction: The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective and more toxic than modern antibiotics. In vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomised controlled study is necessary for clarification. Methods and analysis: This is a multicentre, investigator-initiated, open-label, randomised controlled superiority 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy for infections caused by carbapenem-resistant Gram-negative bacteria. The study is being conducted in 6 centres in 3 countries (Italy, Greece and Israel). We include patients with hospital-associated and ventilator-associated pneumonia, bloodstream infections and urosepsis. The primary outcome is treatment success at day 14, defined as survival, haemodynamic stability, stable or improved respiratory status for patients with pneumonia, microbiological cure for patients with bacteraemia and stability or improvement of the Sequential Organ Failure Assessment (SOFA) score. Secondary outcomes include 14-day and 28-day mortality as well as other clinical end points and safety outcomes. A sample size of 360 patients was calculated on the basis of an absolute improvement in clinical success of 15% with combination therapy. Outcomes will be assessed by intention to treat. Serum colistin samples are obtained from all patients to obtain population pharmacokinetic models. Microbiological sampling includes weekly surveillance samples with analysis of resistance mechanisms and synergy. An observational trial is evaluating patients who met eligibility requirements but were not randomised in order to assess generalisability of findings. Ethics and dissemination: The study was approved by ethics committees at each centre and informed consent will be obtained for all patients. The
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.